Do analysts rate QUCY or GRAY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is QUCY or GRAY more profitable?

Mainz Biomed's return on equity of 0.00% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Graybug Vision N/A -77.61% -71.34%

Do analysts rate GRAY or ATNM?

Actinium Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 350.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Graybug Vision. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is GRAY or ATNM more profitable?

Graybug Vision's return on equity of -77.61% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Graybug Vision N/A -77.61% -71.34% Actinium Pharmaceuticals N/A -100.85% -47.89%

Do analysts prefer BOLD or GRAY?

Boundless Bio currently has a consensus price target of $4.00, suggesting a potential upside of 185.71%. Given Boundless Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Boundless Bio is more favorable than Graybug Vision. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BOLD or GRAY more profitable?

Boundless Bio's return on equity of -53.60% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -53.60% -34.66% Graybug Vision N/A -77.61% -71.34%

Is GRAY or VIRI more profitable?

Graybug Vision's return on equity of -77.61% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Graybug Vision N/A -77.61% -71.34% Virios Therapeutics N/A -130.33% -115.00%

Do analysts prefer TAOX or GRAY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TAOX or GRAY more profitable?

Graybug Vision's return on equity of -77.61% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Graybug Vision N/A -77.61% -71.34%

Graybug Vision (GRAY) Competitors

$1.06 +0.21 (+24.62%)

As of 06/5/2026

Compare

GRAY vs. QUCY, ATNM, BOLD, VIRI, and TAOX

Should you buy Graybug Vision stock or one of its competitors? MarketBeat compares Graybug Vision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Graybug Vision include Mainz Biomed (QUCY), Actinium Pharmaceuticals (ATNM), Boundless Bio (BOLD), Virios Therapeutics (VIRI), and Synaptogenix (TAOX).

How does Graybug Vision compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Mainz Biomed had 6 more articles in the media than Graybug Vision. MarketBeat recorded 6 mentions for Mainz Biomed and 0 mentions for Graybug Vision. Mainz Biomed's average media sentiment score of 0.57 beat Graybug Vision's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Positive
Graybug Vision	Neutral

Mainz Biomed has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Graybug Vision	N/A	-77.61%	-71.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mainz Biomed has higher earnings, but lower revenue than Graybug Vision. Mainz Biomed is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	57.87	-$16.21M	-$47.60	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

49.9% of Graybug Vision shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Mainz Biomed beats Graybug Vision on 9 of the 13 factors compared between the two stocks.

How does Graybug Vision compare to Actinium Pharmaceuticals?

Graybug Vision (NASDAQ:GRAY) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Actinium Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 350.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Graybug Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Graybug Vision has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

In the previous week, Graybug Vision's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Graybug Vision	Neutral
Actinium Pharmaceuticals	Neutral

Graybug Vision's return on equity of -77.61% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Graybug Vision has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Actinium Pharmaceuticals	$90K	348.61	-$48.82M	-$0.75	N/A

Summary

Graybug Vision beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Graybug Vision compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Boundless Bio currently has a consensus price target of $4.00, suggesting a potential upside of 185.71%. Given Boundless Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Boundless Bio is more favorable than Graybug Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

49.9% of Graybug Vision shares are held by institutional investors. 23.1% of Boundless Bio shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Boundless Bio has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

In the previous week, Boundless Bio had 2 more articles in the media than Graybug Vision. MarketBeat recorded 2 mentions for Boundless Bio and 0 mentions for Graybug Vision. Boundless Bio's average media sentiment score of 0.51 beat Graybug Vision's score of 0.00 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Positive
Graybug Vision	Neutral

Boundless Bio's return on equity of -53.60% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Graybug Vision	N/A	-77.61%	-71.34%

Graybug Vision has higher revenue and earnings than Boundless Bio. Boundless Bio is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

Summary

Boundless Bio beats Graybug Vision on 10 of the 14 factors compared between the two stocks.

How does Graybug Vision compare to Virios Therapeutics?

Graybug Vision (NASDAQ:GRAY) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Virios Therapeutics has lower revenue, but higher earnings than Graybug Vision. Virios Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Graybug Vision's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company	Overall Sentiment
Graybug Vision	Neutral
Virios Therapeutics	Neutral

Graybug Vision's return on equity of -77.61% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Virios Therapeutics	N/A	-130.33%	-115.00%

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Graybug Vision beats Virios Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Graybug Vision compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Synaptogenix had 2 more articles in the media than Graybug Vision. MarketBeat recorded 2 mentions for Synaptogenix and 0 mentions for Graybug Vision. Synaptogenix's average media sentiment score of 1.28 beat Graybug Vision's score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Positive
Graybug Vision	Neutral

Synaptogenix has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Synaptogenix has higher earnings, but lower revenue than Graybug Vision. Synaptogenix is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$687.84K	43.13	-$28.74M	-$13.28	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

Graybug Vision's return on equity of -77.61% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Graybug Vision	N/A	-77.61%	-71.34%

Summary

Synaptogenix beats Graybug Vision on 8 of the 13 factors compared between the two stocks.

Get Graybug Vision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAY vs. The Competition

Export

Metric	Graybug Vision	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67M	$968.82M	$6.48B	$12.34B
Dividend Yield	N/A	4.84%	2.67%	5.67%
P/E Ratio	-0.61	1.46	23.96	24.58
Price / Sales	0.00	124.43	536.40	168.09
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.63	8.02	10.47	6.78
Net Income	-$35.60M	-$4.88M	$3.56B	$337.32M
7 Day Performance	N/A	3.26%	0.91%	2.01%
1 Month Performance	55.88%	2.82%	1.86%	3.88%
1 Year Performance	-38.37%	47.16%	25.73%	32.23%

Graybug Vision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAY Graybug Vision	N/A	$1.06 +24.6%	N/A	-38.4%	$1.67M	$426.96M	N/A	27	Gap Up High Trading Volume
QUCY Mainz Biomed	0.8072 of 5 stars	$2.20 -5.6%	N/A	N/A	$34.16M	$537.08K	N/A	30	Gap Up
ATNM Actinium Pharmaceuticals	2.1272 of 5 stars	$1.08 -2.7%	$4.50 +316.7%	-32.2%	$33.89M	$90K	N/A	30
BOLD Boundless Bio	2.9122 of 5 stars	$1.42 -3.4%	$4.00 +181.7%	+33.0%	$33.02M	N/A	N/A	64
VIRI Virios Therapeutics	N/A	$1.68 +4.3%	N/A	-66.9%	$32.35M	N/A	N/A	5	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Graybug Vision (GRAY) Competitors

GRAY vs. QUCY, ATNM, BOLD, VIRI, and TAOX

How does Graybug Vision compare to Mainz Biomed?

Summary

How does Graybug Vision compare to Actinium Pharmaceuticals?

Summary

How does Graybug Vision compare to Boundless Bio?

Summary

How does Graybug Vision compare to Virios Therapeutics?

Summary

How does Graybug Vision compare to Synaptogenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY vs. The Competition

Graybug Vision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Graybug Vision (GRAY) Competitors

GRAY vs. QUCY, ATNM, BOLD, VIRI, and TAOX

How does Graybug Vision compare to Mainz Biomed?

Does the media prefer QUCY or GRAY?

Which has more volatility & risk, QUCY or GRAY?

Is QUCY or GRAY more profitable?

Do analysts rate QUCY or GRAY?

Which has better earnings & valuation, QUCY or GRAY?

Do institutionals & insiders hold more shares of QUCY or GRAY?

Summary

How does Graybug Vision compare to Actinium Pharmaceuticals?

Do analysts rate GRAY or ATNM?

Do institutionals and insiders have more ownership in GRAY or ATNM?

Which has more volatility and risk, GRAY or ATNM?

Does the media refer more to GRAY or ATNM?

Is GRAY or ATNM more profitable?

Which has stronger valuation & earnings, GRAY or ATNM?

Summary

How does Graybug Vision compare to Boundless Bio?

Do analysts prefer BOLD or GRAY?

Do institutionals & insiders have more ownership in BOLD or GRAY?

Which has more risk and volatility, BOLD or GRAY?

Does the media refer more to BOLD or GRAY?

Is BOLD or GRAY more profitable?

Which has higher earnings & valuation, BOLD or GRAY?

Summary

How does Graybug Vision compare to Virios Therapeutics?

Which has more volatility & risk, GRAY or VIRI?

Which has preferable earnings and valuation, GRAY or VIRI?

Does the media refer more to GRAY or VIRI?

Is GRAY or VIRI more profitable?

Do institutionals and insiders have more ownership in GRAY or VIRI?

Summary

How does Graybug Vision compare to Synaptogenix?

Do analysts prefer TAOX or GRAY?

Do institutionals and insiders believe in TAOX or GRAY?

Does the media prefer TAOX or GRAY?

Which has more risk & volatility, TAOX or GRAY?

Which has stronger earnings & valuation, TAOX or GRAY?

Is TAOX or GRAY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY vs. The Competition

Graybug Vision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools